Natco Pharma Share Price Target 2024, 2025, 2030, 2040, 2050
Natco Pharma Ltd (NSE: NATCOPHARM) is a leading Indian pharmaceutical company that specialises in difficult generics and specialized therapies. Many investors wonder about Natco Pharma’s long-term prospects when they consider healthcare and pharma equities.
The article evaluates Natco Pharma’s share price projections for 2024, 2025, 2030, 2040, and 2050 using fundamental analysis and market trends.
What is Natco Pharma Ltd (NSE: NATCOPHARM)?
Contents
- 1 What is Natco Pharma Ltd (NSE: NATCOPHARM)?
- 2 Natco Pharma Share Price Target 2024
- 3 Natco Pharma Share Price Target 2025
- 4 Natco Pharma Share Price Target 2030
- 5 Share Price Target 2040
- 6 Share Price Target 2050
- 7 Should I buy Natco Pharma stock?
- 8 Natco Pharma Ltd Earning Results
- 9 Expert Forecasts on the Future of Natco Pharma Ltd
- 10 Is Natco Pharma stock good to buy?
- 11 Conclusion
- 12 FAQs
Hyderabad-based international pharmaceutical business Natco Pharma was formed in 1981. Development, manufacture, and commercialization of completed dosage formulations and APIs are its specialties. Oncology, hepatitis C, and complicated generics for regulated markets like the US are Natco’s specialties.
Fundamental Table
| Metric | Value |
| Market Cap | ₹27,786.21 Crore |
| P/E Ratio | 12.77 |
| EPS (TTM) | ₹119.53 |
| Dividend Yield | 0.35% |
| ROCE | 27.69% |
| Debt to Equity | 0.06 |
| Promoter Holding | 49.71% |
Natco Pharma can capitalize on its robust product pipeline and worldwide expansion in 2024. The company’s emphasis on complicated generics and specialty therapies could boost growth. R&D and production expenditure should boost its market position.
According to our study, Natco Pharma’s share price objective for 2024 is estimated at ₹800 to ₹1,700.00.
| Year | Minimum Price | Maximum Price |
| 2024 | ₹800 | ₹1700 |
| Month | Minimum Price | Maximum Price |
| January 2024 | ₹800 | ₹900 |
| February 2024 | ₹800 | ₹1100 |
| March 2024 | ₹950 | ₹1050 |
| April 2024 | ₹950 | ₹1050 |
| May 2024 | ₹950 | ₹1050 |
| June 2024 | ₹950 | ₹1250 |
| July 2024 | ₹1100 | ₹1400 |
| August 2024 | ₹1300 | ₹1500 |
| September 2024 | ₹1500 | ₹1700 |
| October 2024 | ₹1600 | ₹1750 |
| November 2024 | ₹1500 | ₹1700 |
| December 2024 | ₹1,600 | ₹1,700 |
Natco Pharma should have increased its product line and enhanced its worldwide footprint by 2025. The company’s biosimilar and niche product expenditures should pay off. Increasing attention on chronic illness segments may boost growth.
Our study predicts a 2025 Natco Pharma share price target range of ₹1,768.64 to ₹1,850.00.
| Year | Minimum Price | Maximum Price |
| 2025 | ₹1,768.64 | ₹1,850.00 |
| Month | Minimum Price | Maximum Price |
| January 2025 | ₹1,768.64 | ₹1,780.00 |
| February 2025 | ₹1,780.00 | ₹1,790.00 |
| March 2025 | ₹1,790.00 | ₹1,800.00 |
| April 2025 | ₹1,800.00 | ₹1,810.00 |
| May 2025 | ₹1,810.00 | ₹1,820.00 |
| June 2025 | ₹1,820.00 | ₹1,825.00 |
| July 2025 | ₹1,825.00 | ₹1,830.00 |
| August 2025 | ₹1,830.00 | ₹1,835.00 |
| September 2025 | ₹1,835.00 | ₹1,840.00 |
| October 2025 | ₹1,840.00 | ₹1,845.00 |
| November 2025 | ₹1,845.00 | ₹1,848.00 |
| December 2025 | ₹1,848.00 | ₹1,850.00 |
Natco Pharma might dominate the global pharmaceutical industry by 2030. The company’s long-term R&D and production efforts should pay off. Growth will come from entering new therapeutic and geographic markets.
Our 2030 Natco Pharma share price estimate is ₹2,495.65 to ₹3,000.00.
| Year | Minimum Price | Maximum Price |
| 2030 | ₹2,495.65 | ₹3,000.00 |
| Month | Minimum Price | Maximum Price |
| January 2030 | ₹2,495.65 | ₹2,550.00 |
| February 2030 | ₹2,550.00 | ₹2,600.00 |
| March 2030 | ₹2,600.00 | ₹2,650.00 |
| April 2030 | ₹2,650.00 | ₹2,700.00 |
| May 2030 | ₹2,700.00 | ₹2,750.00 |
| June 2030 | ₹2,750.00 | ₹2,800.00 |
| July 2030 | ₹2,800.00 | ₹2,850.00 |
| August 2030 | ₹2,850.00 | ₹2,900.00 |
| September 2030 | ₹2,900.00 | ₹2,925.00 |
| October 2030 | ₹2,925.00 | ₹2,950.00 |
| November 2030 | ₹2,950.00 | ₹2,975.00 |
| December 2030 | ₹2,975.00 | ₹3,000.00 |
In 2040, Natco Pharma is expected to dominate complicated generics and specialty medicines worldwide. The company’s long-term innovation and strategic alliances should pay off. Natco’s versatility and specific expertise should help company flourish as healthcare demands change.
We predict a Natco Pharma share price objective of ₹5,000.00 to ₹7,000.00 for 2040.
| Year | Minimum Price | Maximum Price |
| 2040 | ₹5,000.00 | ₹7,000.00 |
| Month | Minimum Price | Maximum Price |
| January 2040 | ₹5,000.00 | ₹5,250.00 |
| February 2040 | ₹5,250.00 | ₹5,500.00 |
| March 2040 | ₹5,500.00 | ₹5,750.00 |
| April 2040 | ₹5,750.00 | ₹6,000.00 |
| May 2040 | ₹6,000.00 | ₹6,200.00 |
| June 2040 | ₹6,200.00 | ₹6,400.00 |
| July 2040 | ₹6,400.00 | ₹6,500.00 |
| August 2040 | ₹6,500.00 | ₹6,600.00 |
| September 2040 | ₹6,600.00 | ₹6,700.00 |
| October 2040 | ₹6,700.00 | ₹6,800.00 |
| November 2040 | ₹6,800.00 | ₹6,900.00 |
| December 2040 | ₹6,900.00 | ₹7,000.00 |
Share price projections for 2050 are very speculative. By then, the pharmaceutical environment may have changed drastically. Natco Pharma must adapt to new technology, healthcare demands, and regulatory environments to succeed. We should predict tremendous value increase if the firm stays inventive and develops globally.
We predict a Natco Pharma share price goal of ₹10,000.00 to ₹15,000.00 by 2050.
| Year | Minimum Price | Maximum Price |
| 2050 | ₹10,000.00 | ₹15,000.00 |
| Month | Minimum Price | Maximum Price |
| January 2050 | ₹10,000.00 | ₹10,500.00 |
| February 2050 | ₹10,500.00 | ₹11,000.00 |
| March 2050 | ₹11,000.00 | ₹11,500.00 |
| April 2050 | ₹11,500.00 | ₹12,000.00 |
| May 2050 | ₹12,000.00 | ₹12,500.00 |
| June 2050 | ₹12,500.00 | ₹13,000.00 |
| July 2050 | ₹13,000.00 | ₹13,500.00 |
| August 2050 | ₹13,500.00 | ₹14,000.00 |
| September 2050 | ₹14,000.00 | ₹14,250.00 |
| October 2050 | ₹14,250.00 | ₹14,500.00 |
| November 2050 | ₹14,500.00 | ₹14,750.00 |
| December 2050 | ₹14,750.00 | ₹15,000.00 |
Should I buy Natco Pharma stock?
Strong fundamentals make Natco Pharma stock a good investment. The company’s last-year sales increase of 46.78% exceeded its three-year CAGR of 23.9%. Its 23.71% ROE indicates good shareholder money management. Currently trading at ₹1,552.85, the company has a fair P/E ratio of 16.98, indicating fair value compared to peers. Investors should be aware of its volatility, with a 52-week range of ₹725 to ₹1,575. Natco Pharma is a good risky investment.
Natco Pharma Ltd Earning Results
In the latest quarterly results, Natco Pharma reported:
- FY24 consolidated revenue was ₹41,269 million.
- EBITDA margins were steady at 45.5% annually.
- FY24 net profit was ₹13,883 million, with an EPS of ₹77.34 per share.
- Complex generics and specialized US markets remain the company’s emphasis.
| Metric | Value |
| Total Revenue (Q4 FY24) | ₹11,103 Million |
| Pharma Export Formulations | ₹9,549 Million |
| Consolidated Revenue (FY24) | ₹41,269 Million |
| EBITDA (Q4 FY24) | ₹5,393 Million |
| EBITDA (FY24) | ₹18,795 Million |
| EBITDA Margin (Q4 FY24) | 48.6% |
| EBITDA Margin (FY24) | 45.5% |
| Profit Before Tax (Q4 FY24) | ₹4,776 Million |
| Profit Before Tax (FY24) | ₹16,735 Million |
| Profit After Tax (Q4 FY24) | ₹3,863 Million |
| Net Profit (FY24) | ₹13,883 Million |
| EPS (FY24) | ₹77.34 per share |
Expert Forecasts on the Future of Natco Pharma Ltd
Overall, industry professionals are optimistic about Natco Pharma:
- The company’s dominance in complicated generics and specialty therapies
- High growth potential in biosimilars and niche items
- Emerging market expansion possibilities
- Strong product pipeline for US-regulated markets
- Optimise costs and operations
Is Natco Pharma stock good to buy?
Bull Case:
- Complex generics and specialized therapies have high development potential.
- Strong product pipeline and R&D
- Growing globally, particularly in regulated areas
- Strong finances with little debt
- Strategic emphasis on high-growth pharmaceutical sectors
Bear Case:
- Generic drug competition is fierce.
- Key market regulatory issues and price constraints
- Several main goods produce considerable income.
- Currency fluctuations affect international operations
- Possible patent litigation and regulatory hurdles
Overall Prediction Table
| Year | Minimum Price | Maximum Price |
| 2024 | ₹800 | ₹1700 |
| 2025 | ₹1,768.64 | ₹1,850.00 |
| 2030 | ₹2,495.65 | ₹3,000.00 |
| 2040 | ₹5,000.00 | ₹7,000.00 |
| 2050 | ₹10,000.00 | ₹15,000.00 |
Conclusion
Natco Pharma is a promising pharmaceutical venture. Complex generics, specialty therapeutics, and worldwide expansion position the firm for growth. Pharmaceutical investors should consider the industry’s competitiveness and regulatory issues. Before investing, you must study and analyze your financial objectives.
